Cardiol Therapeutics (CRDL) News Today $1.10 +0.03 (+2.80%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.12 +0.02 (+1.82%) As of 05/23/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRDL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Cardiol Therapeutics Reports Q1 2025 Financial ResultsMay 14, 2025 | tipranks.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Given Consensus Rating of "Buy" by AnalystsCardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) has been assigned a consensus rating of "Buy" from the seven ratings firms that are currently covering the firm, MarketBeat reports. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company.May 10, 2025 | marketbeat.comEnvestnet Asset Management Inc. Makes New Investment in Cardiol Therapeutics Inc. (NASDAQ:CRDL)Envestnet Asset Management Inc. bought a new stake in Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 309,684 shares of the company's stock, valued at apMay 8, 2025 | marketbeat.comAdvisorShares Investments LLC Lowers Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL)AdvisorShares Investments LLC decreased its holdings in shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) by 24.6% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 882,488 shares of the company's stock after selling 288,381 shares during theMay 1, 2025 | marketbeat.comCardiol Therapeutics (CRDL) Projected to Post Earnings on MondayCardiol Therapeutics (NASDAQ:CRDL) will be releasing earnings before the market opens on Monday, April 21, Financial Modeling Prep reports.April 20, 2025 | marketbeat.comResearch Analysts Offer Predictions for CRDL Q1 EarningsCardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Analysts at Roth Capital cut their Q1 2025 earnings per share estimates for Cardiol Therapeutics in a research note issued on Wednesday, April 16th. Roth Capital analyst J. Wittes now expects that the company will post earnings per share ofApril 20, 2025 | marketbeat.comCardiol Therapeutics starts phase III trial for heart drugApril 18, 2025 | uk.investing.comRoth MKM Sticks to Its Buy Rating for Cardiol Therapeutics (CRDL)April 18, 2025 | markets.businessinsider.comCardiol Therapeutics (NASDAQ:CRDL) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $9.00 price target on shares of Cardiol Therapeutics in a report on Wednesday.April 18, 2025 | marketbeat.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Receives Consensus Rating of "Buy" from BrokeragesCardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) has been assigned a consensus recommendation of "Buy" from the seven research firms that are presently covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation and two have assigned aApril 15, 2025 | marketbeat.comCardiol Therapeutics Reports Increased Losses Amid Rising ExpensesApril 14, 2025 | tipranks.comWhat is HC Wainwright's Forecast for CRDL FY2025 Earnings?Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Equities research analysts at HC Wainwright dropped their FY2025 earnings per share estimates for Cardiol Therapeutics in a research note issued on Monday, April 7th. HC Wainwright analyst V. Bernardino now forecasts that the company will poApril 12, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Cardiol Therapeutics (NASDAQ:CRDL)HC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of Cardiol Therapeutics in a research note on Monday.April 9, 2025 | marketbeat.comWe're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn RateApril 2, 2025 | finance.yahoo.comCardiol Therapeutics (NASDAQ:CRDL) Releases Earnings Results, Beats Expectations By $0.01 EPSCardiol Therapeutics (NASDAQ:CRDL - Get Free Report) announced its earnings results on Monday. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01.April 1, 2025 | marketbeat.comCardiol Therapeutics (CRDL) Projected to Post Quarterly Earnings on MondayCardiol Therapeutics (NASDAQ:CRDL) will be releasing earnings before the market opens on Monday, April 7, Financial Modeling Prep reports.March 31, 2025 | marketbeat.comTejara Capital Ltd Buys 1,344,167 Shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL)Tejara Capital Ltd increased its stake in shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) by 75.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,115,437 shares of the company's stock after buying an additional 1,344,167 shares during theMarch 19, 2025 | marketbeat.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Receives Average Recommendation of "Buy" from BrokeragesCardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) has received an average recommendation of "Buy" from the seven research firms that are presently covering the company, Marketbeat reports. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating on theMarch 19, 2025 | marketbeat.comShort Interest in Cardiol Therapeutics Inc. (NASDAQ:CRDL) Increases By 26.4%Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) was the target of a significant increase in short interest in February. As of February 28th, there was short interest totalling 1,870,000 shares, an increase of 26.4% from the February 13th total of 1,480,000 shares. Currently, 2.4% of the shares of the company are sold short. Based on an average daily trading volume, of 299,700 shares, the days-to-cover ratio is presently 6.2 days.March 18, 2025 | marketbeat.comCardiol Therapeutics' (CRDL) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $9.00 target price on shares of Cardiol Therapeutics in a research report on Monday.February 24, 2025 | marketbeat.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Receives Average Rating of "Buy" from AnalystsCardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) has been given an average recommendation of "Buy" by the seven analysts that are presently covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendFebruary 22, 2025 | marketbeat.comCardiol Therapeutics says study shows benefit of cannabidiol drug in treating heart failureFebruary 20, 2025 | proactiveinvestors.comCardiol Therapeutics: Bargain Stock Price With Share Price Appreciation CatalystsFebruary 19, 2025 | seekingalpha.comShort Interest in Cardiol Therapeutics Inc. (NASDAQ:CRDL) Drops By 8.3%Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) was the target of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,430,000 shares, a decline of 8.3% from the January 15th total of 1,560,000 shares. Approximately 1.8% of the shares of the company are sold short. Based on an average daily volume of 359,300 shares, the days-to-cover ratio is presently 4.0 days.February 18, 2025 | marketbeat.comRODMAN&RENSHAW Upgrades Cardiol Therapeutics (NASDAQ:CRDL) to Strong-BuyRODMAN&RENSHAW raised shares of Cardiol Therapeutics to a "strong-buy" rating in a report on Tuesday.January 29, 2025 | marketbeat.comCardiol Therapeutics initiated with a Buy at Rodman & RenshawJanuary 28, 2025 | markets.businessinsider.comRodman & Renshaw sets $7 target on Cardiol Therapeutics stockJanuary 28, 2025 | msn.comCardiol Therapeutics (NASDAQ:CRDL) Earns Buy Rating from Analysts at Rodman & RenshawRodman & Renshaw started coverage on shares of Cardiol Therapeutics in a report on Tuesday. They issued a "buy" rating and a $7.00 price target for the company.January 28, 2025 | marketbeat.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Short Interest Up 12.4% in DecemberCardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 1,270,000 shares, an increase of 12.4% from the November 30th total of 1,130,000 shares. Currently, 1.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 483,200 shares, the days-to-cover ratio is currently 2.6 days.January 1, 2025 | marketbeat.comHC Wainwright Has Positive Outlook for CRDL FY2024 EarningsCardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Analysts at HC Wainwright upped their FY2024 EPS estimates for Cardiol Therapeutics in a research report issued to clients and investors on Wednesday, December 18th. HC Wainwright analyst V. Bernardino now anticipates that the company will pDecember 20, 2024 | marketbeat.comPRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent PericarditisDecember 19, 2024 | globenewswire.comCardiol Therapeutics (NASDAQ:CRDL) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $9.00 price objective on shares of Cardiol Therapeutics in a report on Wednesday.December 18, 2024 | marketbeat.com3 Penny Stocks Ready to Break Out in 2025Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to scale operations and launch new products.November 29, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for CRDL FY2024 Earnings?Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Analysts at HC Wainwright upped their FY2024 earnings estimates for shares of Cardiol Therapeutics in a research note issued to investors on Wednesday, November 20th. HC Wainwright analyst V. Bernardino now forecasts that the company will eaNovember 22, 2024 | marketbeat.comEdward Nash Reaffirms Buy Rating for Cardiol Therapeutics: Positive Phase II Data and Strategic Future Trials Boost Market PotentialNovember 21, 2024 | markets.businessinsider.comFY2024 Earnings Forecast for CRDL Issued By Leede FinancialCardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Equities researchers at Leede Financial raised their FY2024 EPS estimates for Cardiol Therapeutics in a research note issued to investors on Tuesday, November 19th. Leede Financial analyst D. Loe now expects that the company will earn ($0.26November 21, 2024 | marketbeat.comRoth Capital Issues Pessimistic Forecast for CRDL EarningsCardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Roth Capital lowered their FY2024 earnings per share estimates for Cardiol Therapeutics in a research report issued on Tuesday, November 19th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings per share of ($0.November 21, 2024 | marketbeat.comCardiol Therapeutics' (CRDL) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $9.00 price objective on shares of Cardiol Therapeutics in a research report on Wednesday.November 20, 2024 | marketbeat.comLeede Financial Has Negative View of CRDL FY2027 EarningsCardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Leede Financial reduced their FY2027 earnings estimates for Cardiol Therapeutics in a research note issued on Tuesday, November 19th. Leede Financial analyst D. Loe now expects that the company will earn $0.16 per share for the year, down frNovember 20, 2024 | marketbeat.comCardiol Therapeutics Reports Promising Phase II ResultsNovember 18, 2024 | markets.businessinsider.comCardiol Therapeutics reports promising Phase II results for recurrent pericarditis therapyNovember 18, 2024 | proactiveinvestors.comCardiol Therapeutics Inc. Added to PRISM Emerging Biotech IndexNovember 13, 2024 | globenewswire.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Sees Large Increase in Short InterestCardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 991,600 shares, an increase of 39.6% from the September 30th total of 710,500 shares. Based on an average trading volume of 414,900 shares, the days-to-cover ratio is presently 2.4 days. Currently, 1.5% of the shares of the company are sold short.October 30, 2024 | marketbeat.comHC Wainwright Issues Negative Outlook for CRDL EarningsCardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Analysts at HC Wainwright reduced their Q3 2024 EPS estimates for Cardiol Therapeutics in a research report issued to clients and investors on Thursday, October 24th. HC Wainwright analyst V. Bernardino now anticipates that the company willOctober 28, 2024 | marketbeat.comCardiol Therapeutics (NASDAQ:CRDL) Rating Reiterated by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $9.00 price objective on shares of Cardiol Therapeutics in a research report on Thursday.October 24, 2024 | marketbeat.comCardiol Therapeutics’ Strategic Advancements Boost Market Potential and Revenue ProjectionsOctober 24, 2024 | markets.businessinsider.comCardiol Therapeutics (CRDL) Gets a Buy from Roth MKMOctober 24, 2024 | markets.businessinsider.comAre Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year?October 22, 2024 | msn.comCardiol Therapeutics to expand clinical program for recurrent pericarditis with MAVERIC-2 trialOctober 22, 2024 | proactiveinvestors.comWholesale inflation remained cool last month in latest sign that price pressures are slowingOctober 12, 2024 | ca.finance.yahoo.com Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address CRDL Media Mentions By Week CRDL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRDL News Sentiment▼1.880.77▲Average Medical News Sentiment CRDL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRDL Articles This Week▼01▲CRDL Articles Average Week Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ATAI News URGN News ORIC News MREO News BNTC News SNDL News TKNO News CKPT News ERAS News HUMA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRDL) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRDL Stock Free CRDL Stock Alerts